Skip to main content
SpringerLink
Log in

Association of in vitro invasiveness and gene expression of estrogen receptor, progesterone receptor, pS2 and plasminogen activator inhibitor‐1 in human breast cancer cell lines

  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

The invasive potential of tumor cells is usually tested either by in vitro invasion assays which evaluate cell spreading ability in basement membrane‐like matrices or by in vivo invasion assays in nude mice. Both methods are laborious and time‐consuming. Tumor invasiveness is accompanied by the changes in expression of various genes. The invasive behavior of cells is therefore represented by certain gene expression patterns. The purpose of this study was to investigate whether expression patterns of several genes are characteristic for the invasiveness of cultured cells. We examined the mRNA levels of estrogen receptor (ER), progesterone receptor (PR), estrogen inducible pS2 and plasminogen activator inhibitor‐1 (PAI‐1) in 23 cell lines derived from benign and malignant breast tissues using a competitive reverse transcription‐polymerase chain reaction (cRT‐PCR) system. We also evaluated the invasiveness of these cell lines by their ability to penetrate into a collagen‐fibroblast matrix. We demonstrate that the gene expression pattern of breast cell lines is clearly associated with its in vitro invasiveness. In general, cells with ER, PR, pS2 but no PAI‐1 expression showed a non‐invasive phenotype, while cells expressing PAI‐1 mRNA but not ER mRNA are invasive. Our study indicates that the invasiveness of breast cancer cell lines is characterized by PAI‐1 gene expression and the lack of ER mRNA. This suggests that PAI‐1 may participate in the invasive process.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Foekens JA, Schmitt M, Van Putten WLJ, Peters HA, Kramer MD, Jänicke F, Klijn JGM: Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. J Clin Oncol 12: 1648–1658, 1994

    PubMed  Google Scholar 

  2. Stonelake PS, Baker PG, Gillespie WM, Dunn JA, Spooner D, Morrison JM, Bundred NJ, Oates GD, Lee MJR, Neoptolemos JP, Chan SY, Baker PR: Steroid receptors, pS2 and cathepsin D in early clinically node-negative breast cancer. Eur J Cancer 30: 5–11, 1994

    Google Scholar 

  3. Stal O, Brisfors A, Carstensen J, Ferraud L, Hatschek T, Nordenskjöld B: The South-East Sweden Breast Cancer Group. Relationships of DNA ploidy, S-phase fraction and hormone receptor status to tumor stage in breast cancers detected by population screening. Int J Cancer 51: 28–33, 1992

    PubMed  Google Scholar 

  4. Alghanem AA, Hussain S: The effect of tumor size and axillary lymph node metastasis on estrogen and progesterone receptors in primary breast cancer. J Surg Oncol 31: 218–221, 1986

    PubMed  Google Scholar 

  5. Clark GM, McGuire WL: Prognostic factors in primary breast cancer. Breast Cancer Res Treat 3 (Suppl): S69–S72, 1983

    PubMed  Google Scholar 

  6. McGuire WL: Hormone receptor in breast cancer. In: Bulbrook RD (ed) Cancer Surveys. Vol 5. Oxford University Press, Oxford, 1986, pp 527–536

    Google Scholar 

  7. Garcia M, Derocq D, Freiss G, Rochefort H: Activation of estrogen receptor transfected into a receptor-negative breast cancer cell line decreases the metastatic and invasive potential of the cells. Proc Natl Acad Sci USA 89: 11538–11542, 1992

    PubMed  Google Scholar 

  8. Masiakowski P, Breathnach R, Bloch J, Gannon F, Krust A, Chambon P: Cloning of cDNA sequences of hormon-regulated genes from the MCF-7 human breast cancer cell line. Nucleic Acids Res 10: 7895–7903, 1982

    PubMed  Google Scholar 

  9. Soubeyran I, Wafflart J, Bonichon F, DeMascarel I, Trojani M, Durand M, Avril A, Coindre JM: Immunohistochemical determination of pS2 in invasive breast carcinomas: a study on 942 cases. Breast Cancer Res Treat 34: 119–128, 1995

    PubMed  Google Scholar 

  10. Racca S, Conti G, Pietribiasi F, Stramignoni D, Tampellini M, Valetto MR, Ghezzo F, Di Carlo F: Correlation between pS2 protein positivity, steroid receptor status and other prognostic factors in breast cancer. Int J Biol Markers 10: 87–93, 1995

    PubMed  Google Scholar 

  11. Foekens JA, Rio MC, Seguin P, VanPutten WL, Fauque J, Nap M, Klijn JG, Chambon P: Prediction of relapse and survival in breast cancer patients by pS2 protein status. Cancer Res 50: 3832–3837, 1990

    PubMed  Google Scholar 

  12. Horiguchi J, Lino Y, Takei H: Expression of pS2 estrogeninducible protein in primary breast cancer. Oncology 53: 12–15, 1996

    PubMed  Google Scholar 

  13. Liotta LA, Goldfarb RH, Brundage R, Siegal GP, Terranova V, Garbisa S: Effect of plasminogen activator (urokinase), plasmin, and thrombin on glycoprotein and collagenous components of basement membrane. Cancer Res 41: 4629–4636, 1981

    PubMed  Google Scholar 

  14. VanMourik JA, Lawrence DA, Loskutoff DJ: Purification of an inhibitor of plasminogen activator (antiactivator) synthesized by endothelial cells. J Biol Chem 259: 14914–14921, 1984

    PubMed  Google Scholar 

  15. Foucré D, Bouchet C, Hacène K, Pourreau-Schneider N, Gentile A, Martin PM, Desplaces A, Oglobine J: Relationship between cathepsin D, urokinase, and plasminogen activator inhibitors in malignant vs benign breast tumours. Br J Cancer 64: 926–932, 1991

    PubMed  Google Scholar 

  16. Jänicke F, Schmitt M, Pache L, Ulm K, Harbeck N, Höfler H, Graeff H: Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Breast Cancer Res Treat 24: 195–208, 1993

    PubMed  Google Scholar 

  17. Grøndahl-Hansen J, Christensen IJ, Rosenquist C, Brünner N, Mouridsen HT, Danø K, Blichert-Toft M: High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res 53: 2513–2521, 1993

    PubMed  Google Scholar 

  18. Sumiyoshi K, Baba S, Sakaguchi S, Urano T, Takada Y, Takada A: Increase in levels of plasminogen activator and type-1 plasminogen activator inhibitor in human breast cancer: possible roles in tumor progression and metastasis. Thromb Res 63: 59–71, 1991

    PubMed  Google Scholar 

  19. Sumiyoshi K, Serizawa K, Urano T, Takada Y, Takada A, Baba S: Plasminogen activator system in human breast cancer. Int J Cancer 50: 345–348, 1992

    PubMed  Google Scholar 

  20. Tong D, Schneeberger C, Leodolter S, Zeillinger R: Quantitative determination of gene expression by competitive reverse transcription-polymerase chain reaction in degraded RNA samples. Anal Biochem 251: 173–177, 1997

    PubMed  Google Scholar 

  21. Kury FD, Schneeberger C, Sliutz G, Kubista E, Salzer H, Medl M, Leodolter S, Swoboda H, Zeillinger R, Spona J: Determination of HER-2/neu amplification and expression in tumor tissue and cultured cells using a simple, phenol free method for nucleic acid isolation. Oncogene 5: 1403–1408, 1990

    PubMed  Google Scholar 

  22. Sedlák J, Sedláková O, Hlavcák P, Hunáková L, Bizik J, Grófová M, Chorváth B: Cell surface phenotype and increased penetration of human multidrug-resistant ovarian carcinoma cells into in vitro collagen-fibroblasts matrix. Neoplasma 43: 389–395, 1996

    PubMed  Google Scholar 

  23. Thompson EW, Paik S, Brünner N, Sommers CL, Zugmaier G, Clarke R, Shima TB, Torri J, Donahue S, Lippman ME, Martin GR, Dickson RB: Association of increased basement membrane invasiveness with absence of estrogen receptor and expression of vimentin in human breast cancer cell lines. J Cell Physiol 150: 534–544, 1992

    PubMed  Google Scholar 

  24. Sommers CL, Byers SW, Thompson EW, Torri JA, Gelmann EP: Differentiation state and invasiveness of human breast cancer cell lines. Breast Cancer Res Treat 31: 325–335, 1994

    PubMed  Google Scholar 

  25. Sliutz G, Eder H, Koelbl H, Tempfer C, Auerbach L, Schneeberger C, Kainz C, Zeillinger R: Quantification of uPA receptor expression in human breast cancer cell lines by cRTPCR. Breast Cancer Res Treat 40: 257–263, 1996

    PubMed  Google Scholar 

  26. Koh KK, Mincemoyer R, Bui MN, Csako G, Pucino F, Guetta V, Waclawiw M, Cannon RO III: Effects of hormonereplacement therapy on fibrinolysis in postmenopausal women. N Engl J Med 336: 683–690, 1997

    PubMed  Google Scholar 

  27. Meilahn EN, Cauley JA, Tracy RP, Macy EO, Gutai JP, Kuller LH: Association of sex hormones and adiposity with plasma levels of fibrinogen and PAI-1 in postmenopausal women. Am J Epidemiol 143: 159–166, 1996

    PubMed  Google Scholar 

  28. Dong G, Schulick AH, DeYoung MB, Dichek DA: Identi-fication of a cis-acting sequence in the human plasminogen activator inhibitor type-1 gene that mediates transforming growth factor-b1 responsiveness in endothelium in vivo. JBiol Chem 271: 29969–29977, 1996

    Google Scholar 

  29. Keeton MR, Curriden SA, VanZonneveld AJ, Loskutoff DJ: Identification of regulatory sequences in the type 1 plasminogen activator inhibitor gene responsive to transforming growth factor-beta. J Biol Chem 266: 23048–23052, 1991

    PubMed  Google Scholar 

  30. Farina AR, Coppa A, Tiberio A, Tacconelli A, Turco A, Colletta G, Gulino A, Mackay AR: Transforming growth factor-beta1 enhances the invasiveness of human MDA-MB-231 breast cancer cells by up-regulating urokinase activity. Int J Cancer 75: 721–730, 1998

    PubMed  Google Scholar 

  31. Herman ME, Katzenellenbogen BS: Alterations in transforming growth factor-alpha and-beta production and cell responsiveness during the progression of MCF-7 human breast cancer cells to estrogen-autonomous growth. Cancer Res 54: 5867–5874, 1994

    PubMed  Google Scholar 

  32. Knabbe C, Zugmaier G, Schmahl M, Dietel M, Lippman ME, Dickson RB: Induction of transforming growth factor-beta by the antiestrogens droloxifene, tamoxifen, and toremifene in MCF-7 cells. Am J Clin Oncol 14 (Suppl 2): S15–S20, 1991

    Google Scholar 

  33. Chen H, Tritton TR, Kenny N, Absher M, Chiu JF: Tamoxifen induces TGF-beta 1 activity and apoptosis of human MCF-7 breast cancer cells in vitro. J Cell Biochem 61: 9–17, 1996

    PubMed  Google Scholar 

  34. Raymond WA, Leong AS: Co-expression of cytokeratin and vimentin intermediate filament proteins in benign and neoplastic breast epithelium. J Pathol 157: 299–306, 1989

    PubMed  Google Scholar 

  35. Deng G, Curriden SA, Wang S, Rosenberg S, Loskutoff DJ: Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? J Cell Biol 134: 1563–1571, 1996

    PubMed  Google Scholar 

  36. Bajou K, Noel A, Gerard RD, Masson V, Brunner N, Hoist-Hansen C, Skobe M, Fusenig NE, Carmeliet P, Collen D, Foidart JM: Absence of host plasminogen activator inhibitor-1 prevents cancer invasion and vacularization. Nat Med 4: 923–928, 1998

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Gynecology, Molecular Oncology Group, University of Vienna, Vienna, Austria

    Dan Tong, Christian Schneeberger, Ingrid Schiebel, Nicole Concin, Sepp Leodolter & Robert Zeillinger

  2. Department of Clinical Pathology, University of Vienna, Vienna, Austria

    Klaus Czerwenka

  3. Cancer Research Institute, Bratislava, Slowakia

    Jan Sedlak

Authors
  1. Dan Tong
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Klaus Czerwenka
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jan Sedlak
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Christian Schneeberger
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ingrid Schiebel
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Nicole Concin
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Sepp Leodolter
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Robert Zeillinger
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tong, D., Czerwenka, K., Sedlak, J. et al. Association of in vitro invasiveness and gene expression of estrogen receptor, progesterone receptor, pS2 and plasminogen activator inhibitor‐1 in human breast cancer cell lines. Breast Cancer Res Treat 56, 91–97 (1999). https://doi.org/10.1023/A:1006262501062

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1006262501062

Search

Navigation